Literature DB >> 19941044

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin.

Eunice Yuen1, Ivelina Gueorguieva, Stephen Wise, Danny Soon, Leon Aarons.   

Abstract

Ethnic differences in warfarin maintenance doses have been documented amongst the three major Asian ethnic groups (Chinese, Malay and Indian) in Singapore. Studies have shown that cytochrome P450 2C9 (CYP2C9) polymorphisms alone did not entirely account for these differences. Recent reports suggest that VKORC1 (subunit of vitamin K epoxide reductase) haplotypes are more predictive of warfarin response. Population pharmacokinetic/pharmacodynamic (PK/PD) modelling techniques were employed to characterise the PK and PD of warfarin in a healthy volunteer study of 16 Chinese and Indian subjects following a single 25 mg dose of warfarin. To further investigate the underlying differences in warfarin response, a semi-mechanistic modelling approach (using an indirect response model for PCA activity) incorporating the vitamin K cycle was attempted using population methods with Bayesian inference. All eight Indian subjects had H7H7 VKORC1 haplotypes and three had either *2/wt or *3/wt CYP2C9 genotypes. Six Chinese subjects had H1H1 VKORC1 haplotypes and one had H1H7. All Chinese subjects were homozygous wt/wt for CYP2C9. Simulations to steady state were performed to examine warfarin response in subjects with different CYP2C9 and VKORC1 polymorphisms. The presence of a single *2 or *3 CYP2C9 allele reduced mean [SE (standard error)] S-warfarin clearance by 35% from 0.276 (0.04) to 0.180 (0.11) l/h. Subjects with VKORC1 haplotype groups of H7H7 had increased mean (SE) C (50,S) (concentration of S-warfarin required to achieve 50% of maximum effect) of 479 (7.3) compared to 206 (6.7) ng/ml in subjects with the H1H1 groups. For subjects with the H1H7 haplotype, mean (SE) C (50,S) increased 1.4 times to 288 (1.3) ng/ml compared to subjects with H1H1 haplotypes. Steady state simulations showed that whilst CYP2C9 polymorphisms affect the PK of warfarin, VKORC1 haplotypes may be better predictors of warfarin response. Since 90% of Chinese subjects had the VKORC1 H1 haplotype and 100% of Indian subjects the H7 haplotype in this study, ethnic differences in warfarin response in this study appear to be linked to differences in VKORC1 haplotypes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19941044     DOI: 10.1007/s10928-009-9138-4

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  35 in total

1.  Bayesian analysis of population PK/PD models: general concepts and software.

Authors:  David J Lunn; Nicky Best; Andrew Thomas; Jon Wakefield; David Spiegelhalter
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

2.  Effect of warfarin on plasma and liver vitamin K levels and vitamin K epoxide reductase activity in relation to plasma clotting factor levels in rats.

Authors:  Y Yamanaka; M Yamano; K Yasunaga; T Shike; K Uchida
Journal:  Thromb Res       Date:  1990-01-15       Impact factor: 3.944

3.  VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation.

Authors:  Christof Geisen; Matthias Watzka; Katja Sittinger; Michael Steffens; Laurynas Daugela; Erhard Seifried; Clemens R Müller; Thomas F Wienker; Johannes Oldenburg
Journal:  Thromb Haemost       Date:  2005-10       Impact factor: 5.249

4.  Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach.

Authors:  Xuemin Jiang; Elaine Y L Blair; Andrew J McLachlan
Journal:  J Clin Pharmacol       Date:  2006-11       Impact factor: 3.126

5.  Vitamin K1, vitamin K1 epoxide and warfarin interrelationships in the dog.

Authors:  D M Carlisle; T F Blaschke
Journal:  Biochem Pharmacol       Date:  1981-11-01       Impact factor: 5.858

6.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

Authors:  Harumi Takahashi; Grant R Wilkinson; Edith A Nutescu; Takashi Morita; Marylyn D Ritchie; Maria G Scordo; Vittorio Pengo; Martina Barban; Roberto Padrini; Ichiro Ieiri; Kenji Otsubo; Toshitaka Kashima; Sosuke Kimura; Shinichi Kijima; Hirotoshi Echizen
Journal:  Pharmacogenet Genomics       Date:  2006-02       Impact factor: 2.089

7.  Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients.

Authors:  Suman Lal; Edwin Sandanaraj; Srinivasa Rao Jada; Ming-Chai Kong; Lai-Heng Lee; Boon-Cher Goh; Soo-Chin Lee; Balram Chowbay
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

8.  Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.

Authors:  Farhad Kamali; Tayyaba Irfan Khan; Barry P King; Richard Frearson; Patrick Kesteven; Peter Wood; Ann K Daly; Hilary Wynne
Journal:  Clin Pharmacol Ther       Date:  2004-03       Impact factor: 6.875

9.  Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.

Authors:  Feng Zhao; Celine Loke; Sheila Clare Rankin; Jia-Yi Guo; How Sung Lee; Tuck Seng Wu; Theresa Tan; Te-Chih Liu; Wan-Liang Lu; Yean-Teng Lim; Qiang Zhang; Boon Cher Goh; Soo Chin Lee
Journal:  Clin Pharmacol Ther       Date:  2004-09       Impact factor: 6.875

10.  Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population.

Authors:  Soo-Chin Lee; Swee-Siang Ng; Johannes Oldenburg; Pei-Yi Chong; Simone Rost; Jia-Yi Guo; Hui-Ling Yap; Sheila Clare Rankin; Hui-Boon Khor; Tiong-Cheng Yeo; Kheng-Siang Ng; Richie Soong; Boon-Cher Goh
Journal:  Clin Pharmacol Ther       Date:  2006-03       Impact factor: 6.875

View more
  16 in total

1.  Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9.

Authors:  Kerenaftali Klein; Ivelina Gueorguieva; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-21       Impact factor: 2.745

Review 2.  Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

Authors:  Stephen B Duffull; Daniel F B Wright; Helen R Winter
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

3.  A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins.

Authors:  Qing Xi Ooi; Daniel F B Wright; R Campbell Tait; Geoffrey K Isbister; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

4.  The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement.

Authors:  Shi-Long Zhong; Yuan Liu; Xi-Yong Yu; Dan Xu; Hong-Hong Tan; Qiu-Xiong Lin; Min Yang; Hai-Yan Lao; Shu-Guang Lin
Journal:  Eur J Clin Pharmacol       Date:  2011-02-12       Impact factor: 2.953

5.  Development of a novel individualized warfarin dose algorithm based on a population pharmacokinetic model with improved prediction accuracy for Chinese patients after heart valve replacement.

Authors:  Yu-Bin Zhu; Xian-Hua Hong; Meng Wei; Jing Hu; Xin Chen; Shu-Kui Wang; Jun-Rong Zhu; Feng Yu; Jian-Guo Sun
Journal:  Acta Pharmacol Sin       Date:  2017-02-20       Impact factor: 6.150

6.  The Creating an Optimal Warfarin Nomogram (CROWN) Study.

Authors:  Todd S Perlstein; Samuel Z Goldhaber; Kerrie Nelson; Victoria Joshi; T Vance Morgan; Lawrence J Lesko; Joo-Yeon Lee; Jogarao Gobburu; David Schoenfeld; Raju Kucherlapati; Mason W Freeman; Mark A Creager
Journal:  Thromb Haemost       Date:  2011-11-24       Impact factor: 5.249

Review 7.  Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.

Authors:  Rohan Shah; Manesh R Patel
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-09-19

8.  Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.

Authors:  Ling Xue; Nick Holford; Xiao-Liang Ding; Zhen-Ya Shen; Chen-Rong Huang; Hua Zhang; Jing-Jing Zhang; Zhe-Ning Guo; Cheng Xie; Ling Zhou; Zhi-Yao Chen; Lin-Sheng Liu; Li-Yan Miao
Journal:  Br J Clin Pharmacol       Date:  2016-11-25       Impact factor: 4.335

9.  Development of a bayesian forecasting method for warfarin dose individualization.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Pharm Res       Date:  2011-02-08       Impact factor: 4.200

10.  Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.

Authors:  Yuan Lu; Jinbo Yang; Haiyan Zhang; Jin Yang
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.